cytomed – cytomed

CytoMed's Technologies

CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf"
immunotherapeutics for a wide range of cancers.

CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using
our proprietary technologies for our customers.


iPSC-γδ NKT Cell Technology
(gdNKT Therapy)


CAR-γδ T Cell Technology
(CTM-N2D Therapy)

CytoMed Therapeutics

Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) focused on engineering more affordable cellular cancer therapies to identify and attack a multitude of solid & hematological cancers.

Read More


View All Publications
B2 miceta-roglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo exp...

Chen C,Du Z,Li Z,Tay JC,Wang S,Zha S,

Immunotherapy 2021, 11: 967

Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers

Tay JC,Wang S,Zha S,

Immunotherapy 2021, 9: 1339

Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy

Chen C,Chi Z,Du SH,Kwang TW,Li Z,Tan WK,Wang S,Xu XH,

PLOS ONE 2021, 11: e0161820

CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice w...

Ng YY,Tay JC,Wang S,

Molecular Therapy 2021, 16: 75

Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenog...

Ang WX,Chen C,Chi Z,Li Z,Ng YY,Tan WK,Tay JC,Toh HC,Wang S,Xiao L,Zeng J,

Molecular Therapy 2021, 17: 421

Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells

Wang S,Wu C,Zeng J,

Scientific Reports 2021, 5: 15262

Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells

Du J,Palanisamy N,Wang S,Zeng J,Zhao Y,

Stem Cells 2021, 25: 1055

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T...

Tang SY,Wang S,Zeng J,

PLOS ONE 2021, 14: e0216815

Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d...

Shahbazi M,Toh HC,Wang S,Wu C,Zeng J,

The Journal of Immunology 2021, 188: 4297

Generation of “off-the-shelf” natural killer cells from peripheral blood cell-derived induced plu...

Tang SY,Toh LL,Wang S,Zeng J,

Stem Cell Reports 2021, 9: 1796